Jump to main content
Jump to site search


Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities

Author affiliations

Abstract

Previously, we designed and synthesized a series of bis-substituted aromatic amide-based histone deacetylase (HDAC) inhibitors. In this study, we report the replacement of a bromine atom by different amides on the phenyl ring of the CAP region. Representative compounds 9d and 10k exhibited low nanomolar IC50 values against HDAC1, which were ten times lower than that of the positive control SAHA. The IC50 of 9d against the human A549 cancer cell line was 2.13 μM. Furthermore, 9d increased the acetylation of histones H3 and H4 in a dose-dependent manner. Moreover, 9d significantly arrested A549 cells at the G2/M phase and induced A549 cell apoptosis. Finally, molecular docking investigation rationalized the high potency of compound 9d.

Graphical abstract: Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities

Back to tab navigation

Supplementary files

Publication details

The article was received on 01 Jun 2019, accepted on 06 Aug 2019 and first published on 20 Aug 2019


Article type: Research Article
DOI: 10.1039/C9MD00306A
Med. Chem. Commun., 2019, Advance Article

  •   Request permissions

    Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities

    D. Ge, L. Han, F. Yang, N. Zhao, Y. Yang, H. Zhang and Y. Chen, Med. Chem. Commun., 2019, Advance Article , DOI: 10.1039/C9MD00306A

Search articles by author

Spotlight

Advertisements